2269 N Stock Overview
An investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
WuXi Biologics (Cayman) Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$62.53 |
| 52 Week High | HK$62.53 |
| 52 Week Low | HK$62.53 |
| Beta | 0.66 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -74.45% |
| 5 Year Change | n/a |
| Change since IPO | -73.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2269 N | MX Life Sciences | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how 2269 N performed against the MX Life Sciences industry.
Return vs Market: Insufficient data to determine how 2269 N performed against the MX Market.
Price Volatility
| 2269 N volatility | |
|---|---|
| 2269 N Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: 2269 N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 2269 N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 12,397 | Chris Chen | www.wuxibiologics.com |
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development, and manufacturing in the People’s Republic of China, North America, Europe, and internationally. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and material supplier activities. The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates.
WuXi Biologics (Cayman) Inc. Fundamentals Summary
| 2269 N fundamental statistics | |
|---|---|
| Market cap | Mex$132.67b |
| Earnings (TTM) | Mex$9.71b |
| Revenue (TTM) | Mex$38.71b |
13.7x
P/E Ratio3.4x
P/S RatioIs 2269 N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2269 N income statement (TTM) | |
|---|---|
| Revenue | CN¥16.55b |
| Cost of Revenue | CN¥9.68b |
| Gross Profit | CN¥6.87b |
| Other Expenses | CN¥2.72b |
| Earnings | CN¥4.15b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Mar 26, 2024
| Earnings per share (EPS) | 0.99 |
| Gross Margin | 41.51% |
| Net Profit Margin | 25.08% |
| Debt/Equity Ratio | 7.7% |
How did 2269 N perform over the long term?
See historical performance and comparison